Quantitative analysis of the admission electrocardiogram identifies patients with unstable coronary artery disease who benefit the most from early invasive treatment

Journal of the American College of Cardiology

Volumn 41, Issue 6, 2003, Pages 905-915

  Holmvang, Lene ^a,d   Clemmensen, Peter ^a   Lindahl, Bertil ^b   Lagerqvist, Bo ^b   Venge, Per ^b   Wagner, Galen ^c   Wallentin, Lars ^b   Grande, Peer ^a  

^a Rigshospitalet   (Denmark)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d Mental Health Services CPH   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

TROPONIN T;

ACUTE HEART INFARCTION; AGE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY RISK; DISEASE SEVERITY; ELECTROCARDIOGRAPHY; HEART MUSCLE REVASCULARIZATION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; PATIENT CODING; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SEX RATIO; ST SEGMENT ELEVATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0037454175     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02970-4     Document Type: Article

References (22)

1. Ohman EM, Armstrong PW, Christenson RH, et al., the GUSTO IIA Investigators. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. N Engl J Med 1996;335:1333-41.
2. Lindahl B, Venge P, Wallentin L, the Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. J Am Coll Cardiol 1997;29:43-8.
3. Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD, the Platelet Receptor inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet 1999;354:1757-62.
4. Holmvang L, Luscher MS, Clemmensen P, Thygesen K, Grande P, the TRIM Study Group. Very early risk stratification using combined ECG and biochemical assessment in patients with unstable coronary artery disease: a ThRombin Inhibition in Myocardial ischemia (TRIM) substudy. Circulation 1998;98:2004-9.
5. Newby LK, Christenson RH, Ohman EM, et al., the GUSTO-IIa Investigators. Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. Circulation 1998;98:1853-9.
6. Diderholm E, Andren B, Frostfeldt G, et al. ST depression in ECG at entry indicates severe coronary lesions and large benefits of an early invasive treatment strategy in unstable coronary artery disease: the FRISC II ECG substudy. Eur Heart J 2002;23:41-9.
7. Diderholm E, Andren B, Frostfeldt G, et al. The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: the FRISC II invasive troponin T electrocardiogram substudy. Am Heart J 2002;143:760-7.
8. The FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Invasive compared with non-invasive treatment in unstable coronary artery disease. FRISC II prospective randomised multicentre study. Lancet 1999;354:708-15.
9. The FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Long-term low-molecular-mass heparin in unstable coronary artery disease. FRISC II prospective randomised multicentre study. Lancet 1999;354:701-7.
10. Holmvang L, Clemmensen P, Wagner G, Grande P. Admission standard electrocardiogram for early risk stratification in patients with unstable coronary artery disease not eligible for acute revascularization therapy: a ThRombin Inhibition in Myocardial infarction (TRIM) substudy. Am Heart J 1999;137:24-33.
11. Hyde TA, French JK, Wong CK, Straznicky IT, Whitlock RM, White HD. Four-year survival of patients with acute coronary syndromes without ST-segment elevation and prognostic significance of 0.5-mm ST-segment depression. Am J Cardiol 1999;84:379-85.
12. Kaul P, Fu Y, Chang WC, et al., the Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network (PARAGON-A) and GUSTO-IIb Investigators. Prognostic value of ST-segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. J Am Coll Cardiol 2001;38:64-71.
13. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST-elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000;284:835-42.
14. Boersma E, Pieper KS, Steyerberg EW, et al., the PURSUIT Investigators. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: results from an international trial of 9461 patients. Circulation 2000;101:2557-67.
15. Sätre H, Holmvang L, Wagner GS, Lindahl B, Wallentin L. Reduction of myocardial damage by prolonged treatment with subcutaneous low molecular weight heparin in unstable coronary artery disease. Eur Heart J 1999;20:645-52.
16. Tardiff BE, Califf RM, Tcheng JE, et al., the Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II (IMPACT-II) Investigators. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. J Am Coll Cardiol 1999;33:88-96.
17. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998;31:241-51.
18. Bertinchant JP, Polge A, Ledermann B, et al. Relation of minor cardiac troponin I elevation to late cardiac events after uncomplicated elective successful percutaneous transluminal coronary angioplasty for angina pectoris. Am J Cardiol 1999;84:51-7.
19. Akkerhuis KM, Alexander JH, Tardiff BE, et al. Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different? Circulation 2002;105:554-6.
20. Sadanandan S, Cannon CP, Dibattiste PM, et al. Outcomes of patients with spontaneous versus post PCI CK-MB elevation: data from the TACTICS-TIMI-18 trial (abstr). Presented at: AHA Scientific Session 2001. ID #3290. Available at: www.aha.agora.com/abstractviewer/results.asp.
21. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-87.
22. Boersma E, Akkerhuis KM, Theroux P, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation 1999;100:2045-8.